Cara Therapeutics discontinues neurological condition study as drug fails (updated)

Tvardi Therapeutics

12/06/2024 22:40

(Adds details on study and background in paragraphs 2-3)
       June 12 (Reuters) - Cara Therapeutics  CARA.O  said on
Wednesday it will discontinue a mid-to-late stage study for a
neurological condition that causes itching after its oral drug
did not show meaningful clinical benefit versus a placebo.
    The company said its experimental oral version of the drug
difelikefalin did not show a meaningful improvement in itching
at any dose.
    Notalgia paresthetica is a neurological condition that
causes intense itching, burning or a tingling sensation near the
shoulder blades.

 (Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona
and Shounak Dasgupta)
 ((Puyaan.Singh@thomsonreuters.com))